It is now more than 50 years since the first attempts to carry out biometry were made using an ultrasound A-scan. As we can see from the cover story in this issue, there have been huge advances in the technologies available to ophthalmic surgeons. Howe…
Sclerotherapy Wins for Treating Orbital Vascular Abnormalities
(MedPage Today) — Surgery no longer needed for most lymphatic malformations in the orbital area, study finds.
VIDEO: Speaker discusses conjunctivochalasis
At the Kiawah Eye 2015 meeting, Alan Kozarsky, MD, gives an overview of conjunctivochalasis.
Human Color Vision Gives People the Ability to See Nanoscale Differences
WASHINGTON–(BUSINESS WIRE)–Researchers have harnessed the human eye’s ability to detect subtle color differences and identify ‘thin films’ that differ in thickness by a few nanometers, about the width of a single virus.
Tyrogenex Presents Phase 1 Study of X-82 for Wet AMD at the International Symposium on Ocular Pharmacology and Therapeutics Clinical
NEEDHAM, Mass. & PALM BEACH GARDENS, Fla.–(BUSINESS WIRE)–Tyrogenex, a privately held company focused on the development of next-generation targeted therapeutics for cancer and ophthalmology, announced data from its phase 1 safety study of X-82 at ISOPT.
Presbia Reaches the Halfway Mark in Second Stage Enrollment in the US FDA Pivotal Study
DUBLIN–(BUSINESS WIRE)–Presbia PLC (NASDAQ: LENS), an ophthalmic device company that has developed and is currently marketing the Presbia Flexivue Microlens™, a revolutionary optical lens implant for treating presbyopia today announced that it has treated over 50% of subjects in the second stage enrollment of its pivotal study. Presbia received FDA approval to commence the second stage of its pivotal study in February, and continues enrollment of subjects at eleven investigational sites acros